Evidence map›Paper›PMID 39209567›Full record

ArticleClinical lymphoma, myeloma & leukemia2025

Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma.

Mark A Fiala, Mengmeng Ji, Yi-Hsuan Shih, John Huber, Mei Wang, Kimberly J Johnson, Hamlet Gasoyan, Rong Wang, Graham A Colditz, Shi-Yi Wang and 1 more

Abstract read
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mark A FialaDivision of Oncology, Washington University School of Medicine, St Louis MO. Electronic address: mfiala@wustl.edu.
Mengmeng JiDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis MO.
Yi-Hsuan ShihDepartment of Electrical & Systems Engineering, Washington University School of Medicine, St Louis MO.
John HuberDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis MO.
Mei WangDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis MO.
Kimberly J JohnsonBrown School of Social Work, Washington University School of Medicine, St Louis MO.
Hamlet GasoyanDepartment of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland OH.
Rong WangDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven CT.
Graham A ColditzDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis MO.
Shi-Yi WangDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven CT.
Su-Hsin ChangDepartment of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St Louis MO.

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reductionU01CA265735 · NCI · WASHINGTON UNIVERSITY · PI CHANG, SU-HSIN, WANG, SHIYI · 2021 to 2025
$3.2M
Addressing racial disparities in monoclonal gammopathy of undetermined significance and progression to multiple myeloma from a prevention perspectiveR01CA253475 · NCI · WASHINGTON UNIVERSITY · PI CHANG, SU-HSIN · 2020 to 2022
$1.1M
NCATS NIH HHS UL1 TR002345NCI NIH HHS R01 CA253475NCI NIH HHS U01 CA265735
6 · The paper itself

Abstract

purposeContinuous Medicaid coverage prior to a cancer diagnosis has been associated with earlier detection and better outcomes, for patients with solid tumors. In this study, we aimed to determine if this was observed among patients with multiple myeloma, a hematologic cancer where there are no routine screening tests and most are diagnosed through acute medical events. MATERIALS AND

methodsThis is an analysis of the Merative MarketScan Multistate Medicaid Database, a claims-based dataset. In total, 1105 patients < 65 years old were included in the analyses. Among them, 66% had continuous enrollment (at least 6 months enrollment prior to myeloma), and 34% had discontinuous enrollment (2-6 months enrollment prior to myeloma). Multivariable Cox regression was used to estimate the association between continuous enrollment status and receipt of myeloma treatment within 1 year of index date.

resultsOnly 54% of all Medicaid enrollees received myeloma therapy and only 12% received stem cell transplant within the 1

conclusionPatients with continuous Medicaid coverage prior to diagnosis were less likely to receive myeloma therapy. Future studies should examine whether myeloma patients with continuous Medicaid enrollment have more chronic financial instability and/or higher medical needs and, thus, have higher barriers to care.

Indexed as

Health Services AccessibilityMedicaidMultiple MyelomaAdultFemaleHumansMaleMiddle AgedUnited StatesAccess to careDisparitiesDisparityHealth inequitiesSocial determinants of health

Identifiers

PMID39209567
PMCPMC12179426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.